Immunovant Inc Cash Flow Conversion Efficiency
Immunovant Inc cash flow conversion efficiency. Based on the latest financial reports, Immunovant Inc (IMVT) has a cash flow conversion efficiency ratio of -0.169x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-124.41 Million) by net assets ($735.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immunovant Inc (2018–2026)
Cash flow conversion efficiency of Immunovant Inc from 2018 to 2026. This chart illustrates how Immunovant Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Immunovant Inc for real-time trading data and today's change.
Immunovant Inc Cash Flow Conversion Ratio Explained
Immunovant Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immunovant Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunovant Inc ranked by their cash flow conversion efficiency. Also see market cap of Immunovant Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dongxing Sec Co Ltd
SHG:601198
|
-0.113x |
|
Zhuzhou CRRC Times Electric Co Ltd
SHG:688187
|
0.066x |
|
Accelleron Industries AG
SW:ACLN
|
0.290x |
|
YTL Corporation Bhd
KLSE:4677
|
0.021x |
|
News Corp B
NASDAQ:NWS
|
0.024x |
|
Weatherford International plc
NASDAQ:WFRD
|
0.158x |
|
Belite Bio Inc ADR
NASDAQ:BLTE
|
0.000x |
|
Shenzhen Kaifa Technology Co Ltd
SHE:000021
|
0.038x |
Annual Cash Flow Conversion Efficiency for Immunovant Inc (2018–2026)
The table below shows the annual cash flow conversion efficiency of Immunovant Inc from 2018 to 2026. Review financial agility of Immunovant Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $852.59 Million | $-407.31 Million | -0.478x | +10.08% |
| 2025-03-31 | $707.45 Million | $-375.87 Million | -0.531x | -53.21% |
| 2024-03-31 | $617.76 Million | $-214.23 Million | -0.347x | +33.20% |
| 2023-03-31 | $362.49 Million | $-188.19 Million | -0.519x | -129.87% |
| 2022-03-31 | $469.82 Million | $-106.11 Million | -0.226x | -6.11% |
| 2021-03-31 | $391.48 Million | $-83.33 Million | -0.213x | +62.47% |
| 2020-03-31 | $94.07 Million | $-53.36 Million | -0.567x | +99.95% |
| 2019-03-31 | $24.55K | $-28.55 Million | -1162.716x | -1456.43% |
| 2018-03-31 | $-1.50 Million | $-128.30 Million | 85.719x | -- |
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinat… Read more